نتائج البحث - Lode J. Swinnen

تنقيح النتائج
  1. 1
    Methylation Status of the Epstein-Barr Virus Major Latent Promoter C in Iatrogenic B Cell Lymphoproliferative Disease

    Methylation Status of the Epstein-Barr Virus Major Latent Promoter C in Iatrogenic B Cell Lymphoproliferative Disease حسب Qian Tao, Lode J. Swinnen, Jie Yang, Gopesh Srivastava, Keith D. Robertson, Richard F. Ambinder

    منشور في 1999
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1

    Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1 حسب Wida S. Cherikh, H. Myron Kauffman, Maureen McBride, Jude Maghirang, Lode J. Swinnen, Douglas W. Hanto

    منشور في 2003
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma

    Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma حسب Matthias Holdhoff, Maciej M. Mrugała, Christian Grommes, Thomas Kaley, Lode J. Swinnen, Carlos A. Perez-Heydrich, Lakshmi Nayak

    منشور في 2020
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)

    Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperati... حسب Kristen N. Ganjoo, Fangxin Hong, Sandra J. Horning, Randy D. Gascoyne, Yasodha Natkunam, Lode J. Swinnen, Thomas M. Habermann, Brad S. Kahl, Ranjana H. Advani

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

    Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study حسب Sandra J. Horning, Malik E. Juweid, Heiko Schöder, Gregory A. Wiseman, Alex McMillan, Lode J. Swinnen, Ranjana H. Advani, Randy D. Gascoyne, Andrew Quon

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404)

    Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404) حسب Lode J. Swinnen, Hailun Li, Andrew Quon, Randy D. Gascoyne, Fangxin Hong, Erik A. Ranheim, Thomas M. Habermann, Brad S. Kahl, Sandra J. Horning, Ranjana H. Advani

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage

    Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage حسب Genevieve M. Crane, Helen Powell, Rumen Kostadinov, Patrick Tim Rocafort, Dena E. Rifkin, Peter C. Burger, Richard F. Ambinder, Lode J. Swinnen, Michael J. Borowitz, Amy S. Duffield

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

    Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder حسب Lode J. Swinnen, Michael LeBlanc, Thomas M. Grogan, Leo I. Gordon, Patrick J. Stiff, Alan M. Miller, Yvette L. Kasamon, Thomas P. Miller, Richard I. Fisher

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients

    Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients حسب Lode J. Swinnen, Maria Rosa Costanzo‐Nordin, Susan G. Fisher, E. Jeanne O'Sullivan, Maryl R. Johnson, Alain Heroux, George J. Dizikes, R Pifarré, Richard I. Fisher

    منشور في 1990
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS

    EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS حسب Carlos V. Payá, John J. Fung, Michael A. Nalesnik, Elliott Kieff, Michael Green, Gregory Gores, Thomas M. Habermann, Russell H. Wiesner, Lode J. Swinnen, E. Steve Woodle, Jonathan S. Bromberg

    منشور في 1999
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

    Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide حسب Laura Schoch, Kenneth R. Cooke, Nina D. Wagner‐Johnston, Ivana Gojo, Lode J. Swinnen, Philip Imus, Ephraim J. Fuchs, Mark J. Levis, Richard F. Ambinder, Richard J. Jones, Douglas E. Gladstone

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning

    Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning حسب Yvette L. Kasamon, Richard L. Wahl, Harvey A. Ziessman, Amanda L. Blackford, Steven N. Goodman, Caroline A. Fidyk, Kathryn Rogers, Javier Bolaños‐Meade, Michael J. Borowitz, Richard F. Ambinder, Richard J. Jones, Lode J. Swinnen

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

    Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma حسب Yvette L. Kasamon, Heather A. Jacene, Christopher D. Gocke, Lode J. Swinnen, Douglas E. Gladstone, Brandy Perkins, Brian K. Link, Leslie Popplewell, Thomas M. Habermann, Joseph M. Herman, William Matsui, Richard J. Jones, Richard F. Ambinder

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma

    Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma حسب Jennifer A. Kanakry, Yvette L. Kasamon, Christopher D. Gocke, Hua-Ling Tsai, Janice Davis‐Sproul, Nilanjan Ghosh, Heather J. Symons, Javier Bolaños‐Meade, Douglas E. Gladstone, Lode J. Swinnen, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Richard F. Ambinder

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402

    Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402 حسب Brad S. Kahl, Fangxin Hong, Michael E. Williams, Randy D. Gascoyne, Lynne I. Wagner, John C. Krauss, Thomas M. Habermann, Lode J. Swinnen, Stephen J. Schuster, Christopher G. Peterson, Mark D. Sborov, Sabrina Martín, Matthias Weiss, W. Christopher Ehmann, Sandra J. Horning

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

    Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402 حسب Michael E. Williams, Fangxin Hong, Randy D. Gascoyne, Lynne I. Wagner, John C. Krauss, Thomas M. Habermann, Lode J. Swinnen, Stephen J. Schuster, Christopher G. Peterson, Mark D. Sborov, Sabrina Martín, Matthias Weiss, W. Christopher Ehmann, Sandra J. Horning, Brad S. Kahl

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide

    Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide حسب Yvette L. Kasamon, Richard F. Ambinder, Ephraim J. Fuchs, Marianna Zahurak, Gary L. Rosner, Javier Bolaños‐Meade, Mark J. Levis, Douglas E. Gladstone, Carol Ann Huff, Lode J. Swinnen, William Matsui, Ivan Borrello, Robert A. Brodsky, Richard J. Jones, Leo Luznik

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

    Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101 حسب Tracy T. Batchelor, Sharmila Giri, Amy S. Ruppert, Susan M. Geyer, Scott E. Smith, Nimish Mohile, Lode J. Swinnen, Jonathan W. Friedberg, Brad S. Kahl, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson, Nina D. Wagner‐Johnston, Lakshmi Nayak, John P. Leonard, James L. Rubenstein

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation

    Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation حسب Yvette L. Kasamon, Ephraim J. Fuchs, Marianna Zahurak, Gary L. Rosner, Heather J. Symons, Douglas E. Gladstone, Carol Ann Huff, Lode J. Swinnen, Robert A. Brodsky, William Matsui, Ivan Borrello, Satish Shanbhag, Kenneth R. Cooke, Richard F. Ambinder, Leo Luznik, Javier Bolaños‐Meade, Richard J. Jones

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation

    Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation حسب Philip Imus, Amanda L. Blackford, Maria Bettinotti, Brian Iglehart, August Dietrich, Noah Tucker, Heather J. Symons, Kenneth R. Cooke, Leo Luznik, Ephraim J. Fuchs, Robert A. Brodsky, William Matsui, Carol Ann Huff, Douglas E. Gladstone, Richard F. Ambinder, Ivan Borrello, Lode J. Swinnen, Richard J. Jones, Javier Bolaños‐Meade

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: